• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

For Consumers

  • Print
  • Share
  • E-mail

April 27, 2011 FDA Antiviral Advisory Committee meeting background materials available: boceprevir for Hepatitis C

Background materials for the April 27 FDA Antiviral Advisory Committee meeting to discuss boceprevir, a direct acting antiviral (DAA) intended for the treatment of hepatitis C are available on the FDA web site through the following links...
 

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration